Diasorin Logo

Diasorin

Develops immunodiagnostic and molecular diagnostic kits and systems for healthcare and research.

DIA | XMIL

Overview

Corporate Details

ISIN(s):
IT0003492391 (+2 more)
LEI:
8156002878BDF0EE4348
Country:
Italy
Address:
VIA CRESCENTINO, SNC, 13040 SALUGGIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Diasorin is a global leader in the in vitro diagnostics (IVD) market, specializing in the development, manufacturing, and commercialization of reagent kits and automated systems. The company's core focus is on two primary segments: immunodiagnostics and molecular diagnostics. In immunodiagnostics, Diasorin provides advanced solutions, including its LIAISON® family of analyzers, which detect antibodies and antigens to aid in the diagnosis of diseases. Its molecular diagnostics division offers flexible tools that use targeted and multiplex technologies to identify pathogens in biological specimens, providing healthcare providers with critical, actionable information. The company also operates in the Licensed Technology sector, offering platforms for biomedical research, clinical diagnostics, and drug discovery to help scientists find rapid and reliable answers to complex biological questions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 10:42
Director's Dealing
Comunicato Internal Dealing
Italian 94.9 KB
2025-11-05 17:44
Regulatory Filings
Diasorin 9M 2025 Results Presentation
Italian 2.2 MB
2025-11-05 17:43
Earnings Release
Diasorin’s Board of Directors approves results for the first 9 months of 2025. …
English 362.4 KB
2025-11-05 17:42
Earnings Release
Il Consiglio di Amministrazione di Diasorin approva i risultati dei primi 9 mes…
Italian 478.5 KB
2025-10-07 10:03
Declaration of Voting Results & Voting Rights Announcements
Communication on total amount of voting rights
English 229.7 KB
2025-10-07 10:01
Declaration of Voting Results & Voting Rights Announcements
Comunicazione dell'ammontare complessivo dei diritti di voto
Italian 210.3 KB
2025-09-05 10:34
Declaration of Voting Results & Voting Rights Announcements
Communication on total amount of voting rights
English 206.3 KB
2025-09-05 10:32
Declaration of Voting Results & Voting Rights Announcements
Comunicazione dell'ammontare complessivo dei diritti di voto
Italian 209.6 KB
2025-08-07 11:29
Interim / Quarterly Report
Interim Financial Report as at June 30, 2025
English 3.0 MB
2025-08-04 16:51
Report Publication Announcement
Pubblicazione della Relazione finanziaria semestrale al 30 giugno 2025
Italian 184.4 KB
2025-08-04 15:32
Interim / Quarterly Report
Relazione Finanziaria Semestrale del Gruppo Diasorin al 30 giugno 2025
Italian 3.4 MB
2025-07-31 16:24
Investor Presentation
Diasorin H1 2025 Results Presentation
English 1.4 MB
2025-07-31 16:22
Earnings Release
Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed
English 342.3 KB
2025-07-31 16:21
Earnings Release
Ricavi in crescita ed incremento della marginalità nel 1° semestre 2025. Confer…
Italian 470.4 KB
2025-07-07 09:34
Declaration of Voting Results & Voting Rights Announcements
Communication on total amount of voting rights
English 210.5 KB

Automate Your Workflow. Get a real-time feed of all Diasorin filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Diasorin

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Diasorin via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.